Europe Castrate-Resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Country, Industry Analysis and Forecast, 2020 - 2026

Market Report Description

The Europe Castrate-resistant Prostate Cancer Market would witness market growth of 7.9% CAGR during the forecast period (2020-2026). Owing to the growing prevalence of CRPC, leading market players are expanding themselves into emerging economies by executing strategies like diversification of product portfolios. Moreover, companies invest heavily to accelerate advancement in the development of new medicines. Additionally, the expected launch of new products and increasing awareness of prostate cancer are likely to augment the market growth rate during the forecast period. Furthermore, the rising adoption of novel drugs and a solid pipeline are factors that propel market growth over the forecast period.

The increasing technological advancement in the diagnostic tests which detect prostate cancer will drive the growth of the castrate resistant prostate cancer market. Detection of prostate cancer is very important in order to provide treatment for the patients. With the emergence of more technical advanced equipment for detecting prostate cancer, the market growth will augment over the forecast years.

To detect castration-resistant prostate cancer, tumor marker, staging test biopsy, and prostate imaging are required. These technologies identify prostate cancer at early stages which gives more time to patients to get proper treatment. This further accelerates the growth of the Castrate-resistant Prostate Cancer market.

Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: Castrate-Resistant Prostate Cancer Market in Europe is expected to register a CAGR of 7.9% during the forecast period (2020-2026)

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Scope of the Study

Market Segments Covered in the Report:

By Therapy

• Hormonal Therapy
• Immunotherapy
• Chemotherapy
• Radiotherapy

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• Sanofi S.A.
• Johnson and Johnson
• Pfizer, Inc.
• Bayer AG
• Abbott Laboratories
• GlaxoSmithKline PLC (GSK)
• Northwest Biotherapeutics, Inc.
• Active Biotech AB
• Astellas Pharma, Inc.
• Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)